CEO Update - 29 April 2024

Election week

Much of the UK will go to the polls this Thursday in the biggest test of public opinion ahead of the UK general election. Ten key metro mayoral contests take place including in Tees Valley, Manchester, the West and East Midlands and London. The results will be announced over the weekend and give a new mandate to key figures in regions of the UK whilst also helping define if we will have a summer or autumn general election. In Scotland, despite no elections, the first minister resigned earlier today. Watch this space for an analysis coming next week.

It’s one reason why we’ve focused on long-established relationships with senior parliamentarians this quarter. From launching the Labour Party’s Life Science Sector Strategy in Stevenage in January to hosting Science Minister Andrew Griffith MP at our Gala Dinner, we continue representing the sector at the highest levels. Outside of the pre-election political spotlight, but no less important, the BIA has continued to engage with senior civil servants to make the innovative life science and biotech sector heard. From the National Technology Adviser to the MHRA and the IPO, we have continued to strengthen our stakeholder relationships. Read our latest report 'Influencing and shaping our sector'.

Getting set for SynBioBeta

It's great to see such a strong UK delegation heading to SynBioBeta's Global Synthetic Biology Conference in California next week. The UK's ability to put together its governmental, academic and industrial base on engineered biology is a competitive advantage which will be demonstrated in full effect there. 2024 is proving to be a breakout year for the profile and strength of this deep biotech community and, if you want to learn more, read the speech by Paul Freemont from a recent Downing Street reception. 

EU Critical Medicines Alliance launched

Last week saw the launch of the EU Critical Medicines Alliance. The Commission has put out a statement, launched a website and published the full list of members, which includes EuropaBio (of which we are a full member) and several other organisations. As this process develops, we will monitor and engage – ensuring our ecosystem has the smoothest engagement on this thorniest of topics. As if no reminder is needed, this week is the week that post-Brexit border checks for many sectors are coming into force – whereas we have secured an important postponement for our sector.

US Biosecure explainer

Thank you to the many members who joined the BIA's webinar on the US Biosecure Act last week (watch the webinar recording). It was really interesting to see how companies are thinking about the implications of this US legislation which, if passed in the second half of the year, will impact biotech company strategy and venture capitalist thinking. What's clear is that the proposal still has some time to go and the details to be fleshed out. As with all business preparation ensuring diversity and security of suppliers, whether it be banks, contracted R&D services, or IT systems is increasingly at the forefront of biotech boards and senior management thinking.

DSIT new appointments  

The Department for Science, Innovation and Technology (DSIT) has announced a new cohort of Non-Executive Directors (NEDs) and the appointment of its new Chief Scientific Adviser. Professor Christopher Johnson will join in July as the new Chief Scientific Adviser. UK Chief Scientific Advisor, Professor Dame Angela McLean DBE welcomed him as 'a leading researcher in cyber security for safety-critical computing systems who brings a wealth of expertise to government'.

DSIT also appointed Dominic Field, Liz Cohen, Gillian Leng (ex-NICE CEO) and Mark Poulton as new Non-Executive Directors to join its board and confirmed the re-appointment of Shonnel Malani as Lead Non-Executive Director alongside Melissa Di Donato, Jason Chin, Saul Klein, Bryan Ingleby and Vikas Shah who remain from the Start-Up Board. I’d welcome insights from BIA members if they work with the newly appointed NEDs and views on whether the DSIT Board has the insight needed to effectively support our life science sector.

Join 'Step up for RNID with the BIA' - our 2024 fundraising challenge 

As Deaf Awareness Week 2024 (6-12 May) approaches rapidly, we have partnered with RNID, our charity partner, to provide valuable resources and initiatives aimed at fostering more inclusive workplaces within the biotech sector. From complimentary digital packs with engaging content and plaque featuring your company's name in BSL to free remote deaf awareness training for you and your team (limited spots available), see how you can get involved and help shape inclusive workplace culture. 

Lastly, starting next Monday, BIA members are invited to take part in the 'Step Up for RNID with the BIA' challenge starting on 6 May, as part of Deaf Awareness Week. The challenge aims to connect the BIA's headquarters in London with hearing research locations worldwide. Assemble your team (up to 10 members), select a target destination (distances ranging from 200 km to 5,000 km) and prepare to commence your journey over the following four weeks (6-31 May). Learn more


As next Monday will be a Bank Holiday in the UK, the next edition of Newscast will go out on Tuesday 7 May.

 

Steve Bates Headshot.png

 

 

Steve Bates OBE
CEO, BioIndustry Association

More news and updates 

Women in Biotech Mentoring Programme: Helen and Kathryn's experience

In this interview, consultant and best-selling author Kathryn Simpson, together with patent attorney Helen Bartlett, dive into their reasons for joining the BIA's Women in Biotech mentoring programme, and how this experience has impacted their professional and personal lives.

Optibrium partners with FMC Corporation to transform agrochemical discovery

Optibrium’s AI-powered discovery platform Cerella™ chosen by FMC to accelerate its agrochemical discovery pipeline.

Deep Biotech companies using engineering biology for good: Solena Materials case study

Solena Materials is a pioneering biotech company spun out from Imperial College London, specialising in the development of computationally designed synthetic protein materials, originally featured in BIA's Deep Biotech report on disruptive innovation for global sustainability.

Touchlight Genetics and NPL awarded grant to develop novel gene-length single-stranded genome editing template

Touchlight Genetics, in partnership with the National Physical Laboratory (NPL) have secured funding from Innovate UK under their Innovative Technologies: Nucleic Acid Medicines Manufacture, Round 2 call. 

CEO Update - 13 May 2024

It was wonderful to celebrate with RNID, our charity partner of the year, the news that pioneering gene therapy has restored a UK girl's hearing. Read on for updates on MHRA AI-Airlock, AMR action plan and more...

PrecisionLife and Metrodora Institute launch clinical trials to accelerate treatment of ME/CFS and long Covid patients

Up to 1,000 patients being recruited into targeted precision medicine clinical trials expected to readout results as early as this year; trials are designed to provide validation of safety and effectiveness for novel diagnostics and innovative clinical care pathways in ME/CFS and Long Covid.

Accelerating biotech innovations and predicting genetic codes: Spotlight on Ingenza

Meet Ian Fotheringham, the Managing Director of Ingenza, a global CRDMO that aims to accelerate clients' journeys from discovery to clinical trials while minimising costs and risks. Their innovative codABLE® algorithm brings predictability to DNA sequence configuration, revolutionizing recombinant production of pharmaceutical and industrial molecules. Join us as we explore Ian's insights and Ingenza's ambitious goals for the future.

European Life Sciences sector primed for growth in 2024 driving real estate demand and investment opportunities

The European Life Science sector has been marked by strong growth and resilience in recent years and is set for significant expansion in 2024, driven by new medical treatments and both private and public funding according to JLL’s Life Sciences Industry & Real Estate Perspective report.

Deep Biotech companies using engineering biology for good: Moa Technology case study

A spin-out from Oxford University, Moa Technology is developing next-generation herbicides to tackle a growing crisis in agriculture. Read more in BIA's Deep Biotech report on disruptive innovation for global sustainability.

Ingenza expanding codABLE® gene design algorithm to aid recombinant protein production in yeast

Scottish CRDMO Ingenza has secured innovation funding to adapt its codABLE® machine learning platform to precisely control recombinant protein expression in the industrial yeast Pichia pastoris. This game-changing project will accelerate the development of therapeutics, enzymes and other proteins by harnessing machine learning to fine-tune codon usage, ensuring seamless compatibility with the production host and maximising production yields.

Arecor and Medtronic Diabetes establish collaboration to develop novel thermostable insulin for implantable pump delivery

Medtronic to fund Arecor’s development of Arestat™ enabled novel, high concentration, thermostable insulin, specifically tailored for use in combination with a next-generation implantable pump

A critical time for AI, dementia and better brain health

Ahead of BioBeat24, Iraida Soria-Espinosa, Senior Innovation & Business Manager at UK DRI, and Miranda Weston-Smith, Founder of BioBeat, caught up with keynote speaker Zoe Kourtzi, Professor of Computational Cognitive Neuroscience at the University of Cambridge.

More within